Next-Generation Bone Marrow Cell Therapies for Cardiac Repair: Integrating Gene Therapy and Bioengineering to Enhance Therapeutic Potency

Mesenchymal stem/stromal cells and regenerative medicine.

Mesenchymal stem/stromal cells (MSCs) continue to drive innovation in regenerative medicine, yet the field is undergoing a critical evolution from the early concept of cellular engraftment to complex paracrine-mediated tissue repair. This review systematically evaluates the core scientific questions defining this trans...

Mesenchymal Stem Cell Therapy for Systemic Sclerosis: Current Evidence and Clinical Applications.

Biological and Methodological Barriers in Cardiac Regeneration: A Review of Current Challenges & Emerging Strategies

Successfully overcoming translational barriers will require standardized trial designs, rigorous product characterization criteria, and greater emphasis on clinically meaningful endpoints.

Harnessing stem cells for regenerative medicine: Current applications and future prospects

A comprehensive literature review of preclinical models and clinical trials focusing on mesenchymal, hematopoietic, and pluripotent stem cells, evaluating their efficacy, safety, and manufacturing challenges found stem cell therapies demonstrate remarkable healing potential.

Stem Cell-Derived Cardiac and Conduction System Cells for Heart Regeneration and Repair: Current Progress and Future Directions.

This review evaluates recent developments in hiPSC technology, beginning with the generation of patient-specific models of inherited arrhythmias and cardiomyopathies, and examines progress in directing hiPSCs into specialized lineages, including cardiomyocytes, pacemaker cells, and Purkinje fibers.

Host Barriers to In Vivo HSC Gene Therapy with Helper-Dependent Adenovirus Vectors

Ex vivo hematopoietic stem cell (HSC) gene therapy strategies have proved effective for the treatment of various diseases, with recent advances leading to the clinical approval of several cell products. To overcome issues associated with the cost and technical complexity of ex vivo strategies, we turn towards in vivo s...